Overview

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of JTT-302 on the increase of High Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in subjects with low HDL-C levels.
Phase:
Phase 2
Details
Lead Sponsor:
Akros Pharma Inc.